Syncona Expands Global Leadership Position In Gene Therapy With Foundation Of New Companies

Published 14 Jun 2018

Syncona further strengthens position in gene therapy; foundation of SwanBio and Orbit Biomedical takes gene therapy group to five companies.

  • Creation of SwanBio, focused on the Central Nervous System, means Syncona’s portfolio companies now covers every tissue compartment where gene therapy has proof of concept (retina, liver, CNS).
  • Orbit Biomedical founded following the acquisition of leading surgical platform for sub-retinal delivery from Janssen Biotech, Inc. and transfer of key individuals to the Orbit Biomedical management team.
  • Commitments of $35 million (£26.2 million), including $23m (£17.2 million) for a 72 per cent fully diluted stake in SwanBio, and $12 million (£9.0 million)1 to Orbit Biomedical where Syncona owns an 80 per cent fully diluted stake.

Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, today announces the further development of its gene therapy group with the creation of two new companies: SwanBio and Orbit Biomedical.

Chris Hollowood, Chief Investment Officer of Syncona and leader of Syncona’s AAV gene therapy strategy, said:

“We believe that gene therapy represents a whole new way of combatting disease. Syncona has been deeply invested in gene therapy since our founding in 2012. We have sought to build a series of therapeutically focused gene therapy companies around leading clinician researchers in the three human tissue compartments where there is clinical proof of gene therapy’s impact on disease. The creation of SwanBio achieves this part of the strategy bringing the capability to address disease in the Central Nervous System alongside our existing capability in the Retina, through Nightstar and Gyroscope, and Systemically with Freeline. Gene therapy has the potential to be a very important modality for the CNS and in SwanBio we have a fantastic team that brings together gene therapy, disease biology, clinical need and patient engagement.”

“In parallel, we have sought to build leading proprietary platforms for delivery and manufacturing, since these two aspects are essential to the safe and accurate administration of high quality gene therapy products. The foundation of Orbit Biomedical and acquisition of the leading sub-retinal surgical delivery platform from Janssen Biotech, Inc., completes this second part of the strategy, and builds on Freeline’s previous acquisition of a world-leading manufacturing platform from Rentschler. In both these acquisitions we were successful in retaining the teams of key individuals responsible for each platform’s development.

“Orbit Biomedical is an exciting standalone business and an enabling acquisition for Syncona’s retinal gene therapy companies. We look forward to supporting the team as they work to set the standard for sub-retinal delivery and bring gene therapy to all patients who stand to benefit.”

Strengthening a leading gene therapy portfolio

The foundation of these two new companies underlines Syncona’s leadership position in the gene therapy space where it now owns one of the broadest, highest quality, co-ordinated set of gene therapy products, platforms and capabilities globally. These therapeutics are developed through its five group companies, each with their distinct product focus and domain expert teams that ensure high quality and rapid execution. Alongside SwanBio and Orbit Biomedical, the group is comprised of Nightstar (inherited retinal diseases), Freeline (chronic systemic disease) and Gyroscope (retinal inflammation and one of the first companies globally to move gene therapy from rare disease to highly prevalent severe diseases with no treatment options.)

Syncona led the $25 million Series A investment round in SwanBio, committing $23 million over three tranches for a 72 per cent fully diluted stake in the business. In founding Orbit Biomedical, Syncona has committed $12 million in funding for an 80 per cent fully-diluted ownership stake. Syncona is the sole institutional investors in both companies.



Syncona Ltd
Siobhan Weaver
Head of Communications and Investor Relations
Tel: +44 (0) 20 7611 2031

National media/ newswires:
Tulchan Communications
Martin Robinson / Lisa Jarrett-Kerr
Tel: +44 (0) 207 353 4200

Industry and trade media:
Consilium Strategic Communications
Amber Fennell/ Suki Virji/ Chris Welsh
Tel: +44 (0)20 3709 5700

Copies of this press release and other corporate information can be found on the company website at:

About Syncona

Syncona is a leading FTSE250 healthcare company focussed on investing in and building global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders. Our current investment portfolio consists of seven high quality companies in life science and a leading range of fund investments.

We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses. We are established leaders in gene therapy, cell therapy and advanced diagnostics, and focus on delivering dramatic efficacy for patients in areas of high unmet need.

Our market leading funds portfolio seeks to generate superior returns by investing in long only and alternative investment funds. This represents a productively deployed evergreen funding base which enables us to take a long term approach to investing in life sciences as we target the best new opportunities and support our existing portfolio companies to grow and succeed.

Syncona is aligned with two of the premium charitable funders in UK science, the Wellcome Trust, original founder of Syncona, and Cancer Research UK, both of which are significant shareholders in our business. We make a donation of 0.3% of Net Asset Value to a range of charities each year.

About Orbit Biomedical

Orbit Biomedical has the potential to transform the accuracy, safety and consistency of delivering curative therapeutics, including gene therapies, enabling enhanced benefits to patients. The Company’s current focus is delivery to the sub-retinal space for the treatment of retinal disease. Orbit Biomedical’s unique surgical system and training platform is the product of many years’ work within Janssen Biotech, Inc; culminating in clinical data suggesting important advantages of the procedure over standard subretinal injection techniques. Orbit Biomedical’s mission is to revolutionize gene and cell therapy treatment by setting a new standard for precise, targeted surgical delivery. Located in Philadelphia, Orbit Biomedical was founded in 2018 by Syncona and four senior Janssen Biotech, Inc executives who previously led the development of the platform technology and associated clinician education.

About SwanBio

SwanBio Therapeutics is a gene therapy company focused on the development and commercialisation of genetically defined therapies for the treatment of neurological disorders. The Company, which is located in Boston and Philadelphia, is building on its proprietary delivery and manufacturing know-how to enable it to deliver its products commercially which it will leverage for each of its pipeline products. The business is based on work by Florian Eichler, a founder of SwanBio and Associate Professor of Neurology at Harvard Medical School and Assistant in Neurology, Director of the Leukodystrophy Clinic, and Director of the Center for Rare Neurological Diseases at Massachusetts General Hospital. Its lead programme is in development for a monogenic neurodegenerative condition impacting approximately 1 in 17,000 people.

1 All as per exchange rates on 13 June 2018

Syncona Limited Disclaimer

Please read the below disclaimer carefully. You will be asked to accept these terms and conditions before proceeding.

The information on this website is directed only at persons who are shareholders in Syncona Limited (the “Company”) and is provided for their exclusive use and benefit.

Users of this website are responsible for observing all applicable laws and regulations in their relevant jurisdictions before proceeding to access the information contained herein. By proceeding to access the information, users are deemed to be representing and warranting that the applicable laws and regulations of their relevant jurisdiction allow them to do so. No information, materials or opinions contained on this website (“Materials”) constitute or would be deemed to constitute a recommendation or invitation in any jurisdiction to invest or otherwise deal in the shares of the Company (the “Shares”).

The website that you are seeking to access does not constitute an offer to buy or sell the securities mentioned in the website in any jurisdiction or jurisdictions in which such offers or sales are unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In particular, the securities mentioned in the website have not been and will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or exemption from registration under the Securities Act and other securities laws. There will be no public offer of these securities in the United States. Offers and sales of these securities, and distribution of the related information, may also be subject to restrictions in other jurisdictions.

The website that you are seeking to access is not directed at and may not be viewed by or distributed to persons:

  • in the United States or who are U.S persons (as defined in Rule 902 under the Securities Act);


  • located in a jurisdiction where it is not lawful to access the materials.

The Materials are provided on an “as is” and “as available basis” and do not purport to be full or complete. The Company and its affiliates believe that the source of the Materials is reliable however they cannot and do not guarantee, either expressly or implicitly, and accept no liability for, the accuracy, validity, timeliness, merchantability or completeness of any information or data (whether prepared by the Company, its affiliates or by any third party) for any particular purpose or use or that the information or data will be free from error. The Company and its affiliates do not undertake any responsibility for any reliance which is placed by any person on any statements or opinions which are expressed herein. Neither the Company, nor any of its affiliates, directors, officers or employees will be liable or have any responsibility of any kind for any loss or damage that any person may incur resulting from the use of this information.Nothing contained in this website constitutes financial, investment, legal, tax or other advice and is not to be relied on in making an investment or other decision. You should obtain relevant and specific professional advice before making any investment decision.

The Materials on this website are provided for your personal use and informational purposes only and are subject to change without notice. The Company has the right to suspend or withdraw the provision of all or any of the website of the Materials without prior notice at any time.

The value of investments mentioned in this site, and the income from them may go down as well as up and investors may not get back the amount invested. Information on past performance, where given, is not a guide to future performance. Changes in rates of exchange between currencies may cause the value of investments to decrease or increase.
The Company is a registered closed-ended collective investment scheme registered pursuant to the Protection of Investors (Bailiwick of Guernsey) Law, 1987, as amended (the ‘‘POI Law’’) and the Registered Collective Investment Scheme Rules 2008 (the ‘‘CIS Rules’’) issued by the Guernsey Financial Services Commission (the ‘‘GFSC’’). Neither the GFSC nor the States of Guernsey Policy Council take any responsibility for the financial soundness of the Company or for the correctness of any of the statements made or opinions expressed with regard to it.


Copyright of all images and text in this website is owned by or licensed to the Company or one of its affiliates unless otherwise noted. You may imprint, copy, download or temporarily store extracts from this website for your personal information and use. Any other use is prohibited unless you first request and obtain the prior written consent of the Company. You may not alter or otherwise make any changes to any material that you print or download from this website, including, without limitation, removing any identifying marks or legends from such material. In particular, you may not copy or use any part of this website on any other website, or link any other website to this website, without the prior written permission of the Company. You may not use the website for any purpose which is unlawful, abusive, libellous, obscene or threatening.

No Warranty

The Materials contained in this website are provided without any warranty of any kind, either expressed or implied, to the fullest extent permissible pursuant to applicable law. Neither the Company nor its affiliates assume any responsibility for the uninterrupted availability of this website or warrant that it will be error-free, that defects will be corrected, or that this website or the servers that make it available will be free of viruses or other harmful components.

Liability Waiver

You agree that under no circumstances, including, but not limited to, negligence, shall the Company or any of its affiliates be liable for any special or consequential damages that result from the access or use of, or the inability to access or use, the Materials on this website. This does not exclude or restrict any duty or liability that the Company has to its customers under the regulatory system in the United Kingdom or Guernsey.

Privacy Policy

This policy sets out what the Company and its affiliates do with any personal information collected from this website.

Any personal information collected from this website will be processed in accordance with relevant data protection laws.

You may use the public areas of this website without providing the Company or its affiliates with any personal information and the Company and its affiliates do not monitor or collect any personal information through your access to the public areas of this website. The Company and its affiliates do not use cookies to collect information but may gather other anonymous information to assist in improving the services.

If you chose to provide the Company and its affiliates with personal information, this information will only be used for the purposes of the service that you have requested. The Company and its affiliates will not sell or transfer any personal information to third parties without your permission, other than as required by law.

The Company and its affiliates are not responsible for the content or privacy policies of websites to which this website may link.

The Company and its affiliates are committed to protecting your personal information but in the event that the system is infiltrated by unauthorised third parties the Company and its affiliates will not be liable for any resulting misuse of personal information.

Linked Sites

The Company has not reviewed any website linked to this website and is not responsible for the contents of off-site pages or any other websites linked or linking to this website. If you follow any links from this website you do so at your own risk.

Links to this website may not be established without the prior written consent of the Company.

Governing Law

The terms and conditions of this legal notice shall be governed by and construed in accordance with the laws of Guernsey. Users of this website agree that any dispute or action arising out of or relating to these terms or any user’s use of this website shall be commenced only in the courts located in Guernsey, and users of this website hereby consent and submit to the exclusive jurisdiction of such courts for the purposes of any such dispute or action.

By accessing Materials on this website you agree to be bound by the foregoing limitations.